Genetic mechanisms of critical illness in Covid-19
Abstract The subset of patients who develop critical illness in Covid-19 have extensive inflammation affecting the lungs1 and are strikingly different from other patients: immunosuppressive therapy benefits critically-ill patients, but may harm some non-critical cases.2 Since susceptibility to life-threatening infections and immune-mediated diseases are both strongly heritable traits, we reasoned that host genetic variation may identify mechanistic targets for therapeutic development in Covid-19.3GenOMICC (Genetics Of Mortality In Critical Care, <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://genomicc.org">genomicc.org</jats:ext-link>) is a global collaborative study to understand the genetic basis of critical illness. Here we report the results of a genome-wide association study (GWAS) in 2244 critically-ill Covid-19 patients from 208 UK intensive care units (ICUs), representing >95% of all ICU beds. Ancestry-matched controls were drawn from the UK Biobank population study and results were confirmed in GWAS comparisons with two other population control groups: the 100,000 genomes project and Generation Scotland.We identify and replicate three novel genome-wide significant associations, at chr19p13.3 (rs2109069, p = 3.98 × 10−12), within the gene encoding dipeptidyl peptidase 9 (DPP9), at chr12q24.13 (rs10735079, p =1.65 × 10−8) in a gene cluster encoding antiviral restriction enzyme activators (OAS1, OAS2, OAS3), and at chr21q22.1 (rs2236757, p = 4.99 × 10−8) in the interferon receptor gene IFNAR2. Consistent with our focus on extreme disease in younger patients with less comorbidity, we detect a stronger signal at the known 3p21.31 locus than previous studies (rs73064425, p = 4.77 × 10−30).We identify potential targets for repurposing of licensed medications. Using Mendelian randomisation we found evidence in support of a causal link from low expression of IFNAR2, and high expression of TYK2, to life-threatening disease. Transcriptome-wide association in lung tissue revealed that high expression of the monocyte/macrophage chemotactic receptor CCR2 is associated with severe Covid-19.Our results identify robust genetic signals relating to key host antiviral defence mechanisms, and mediators of inflammatory organ damage in Covid-19. Both mechanisms may be amenable to targeted treatment with existing drugs. Large-scale randomised clinical trials will be essential before any change to clinical practice..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 15. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pairo-Castineira, Erola [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2020.09.24.20200048 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018830129 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018830129 | ||
| 003 | DE-627 | ||
| 005 | 20230429093244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200928s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.09.24.20200048 |2 doi | |
| 035 | |a (DE-627)XBI018830129 | ||
| 035 | |a (biorXiv)10.1101/2020.09.24.20200048 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Pairo-Castineira, Erola |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genetic mechanisms of critical illness in Covid-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The subset of patients who develop critical illness in Covid-19 have extensive inflammation affecting the lungs1 and are strikingly different from other patients: immunosuppressive therapy benefits critically-ill patients, but may harm some non-critical cases.2 Since susceptibility to life-threatening infections and immune-mediated diseases are both strongly heritable traits, we reasoned that host genetic variation may identify mechanistic targets for therapeutic development in Covid-19.3GenOMICC (Genetics Of Mortality In Critical Care, <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://genomicc.org">genomicc.org</jats:ext-link>) is a global collaborative study to understand the genetic basis of critical illness. Here we report the results of a genome-wide association study (GWAS) in 2244 critically-ill Covid-19 patients from 208 UK intensive care units (ICUs), representing >95% of all ICU beds. Ancestry-matched controls were drawn from the UK Biobank population study and results were confirmed in GWAS comparisons with two other population control groups: the 100,000 genomes project and Generation Scotland.We identify and replicate three novel genome-wide significant associations, at chr19p13.3 (rs2109069, p = 3.98 × 10−12), within the gene encoding dipeptidyl peptidase 9 (DPP9), at chr12q24.13 (rs10735079, p =1.65 × 10−8) in a gene cluster encoding antiviral restriction enzyme activators (OAS1, OAS2, OAS3), and at chr21q22.1 (rs2236757, p = 4.99 × 10−8) in the interferon receptor gene IFNAR2. Consistent with our focus on extreme disease in younger patients with less comorbidity, we detect a stronger signal at the known 3p21.31 locus than previous studies (rs73064425, p = 4.77 × 10−30).We identify potential targets for repurposing of licensed medications. Using Mendelian randomisation we found evidence in support of a causal link from low expression of IFNAR2, and high expression of TYK2, to life-threatening disease. Transcriptome-wide association in lung tissue revealed that high expression of the monocyte/macrophage chemotactic receptor CCR2 is associated with severe Covid-19.Our results identify robust genetic signals relating to key host antiviral defence mechanisms, and mediators of inflammatory organ damage in Covid-19. Both mechanisms may be amenable to targeted treatment with existing drugs. Large-scale randomised clinical trials will be essential before any change to clinical practice. | ||
| 700 | 1 | |a Clohisey, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Klaric, Lucija |e verfasserin |4 aut | |
| 700 | 1 | |a Bretherick, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Rawlik, Konrad |e verfasserin |4 aut | |
| 700 | 1 | |a Parkinson, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Pasko, Dorota |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Richmond, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Fourman, Max Head |e verfasserin |4 aut | |
| 700 | 1 | |a Russell, Clark D |e verfasserin |4 aut | |
| 700 | 1 | |a Law, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Furniss, James |e verfasserin |4 aut | |
| 700 | 1 | |a Gountouna, Elvina |e verfasserin |4 aut | |
| 700 | 1 | |a Wrobel, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Moutsianas, Loukas |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Meynert, Alison |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Zhijian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhai, Ranran |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Chenqing |e verfasserin |4 aut | |
| 700 | 1 | |a Griffiths, Fiona |e verfasserin |4 aut | |
| 700 | 1 | |a Oosthuyzen, Wilna |e verfasserin |4 aut | |
| 700 | 1 | |a Grimes, Graeme |e verfasserin |4 aut | |
| 700 | 1 | |a Shih, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Keating, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Zechner, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Haley, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Porteous, David J. |e verfasserin |4 aut | |
| 700 | 1 | |a Hayward, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Knight, Julian |e verfasserin |4 aut | |
| 700 | 1 | |a Summers, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Shankar-Hari, Manu |e verfasserin |4 aut | |
| 700 | 1 | |a Klenerman, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Turtle, Lance |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Hinds, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Horby, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Nichol, Alistair |e verfasserin |4 aut | |
| 700 | 1 | |a Maslove, David |e verfasserin |4 aut | |
| 700 | 1 | |a Ling, Lowell |e verfasserin |4 aut | |
| 700 | 1 | |a McAuley, Danny |e verfasserin |4 aut | |
| 700 | 1 | |a Montgomery, Hugh |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Rowan, Kathy |e verfasserin |4 aut | |
| 700 | 1 | |a Fawkes, Angie |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Lee |e verfasserin |4 aut | |
| 700 | 1 | |a Ponting, Chris P. |e verfasserin |4 aut | |
| 700 | 1 | |a Tenesa, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a Caulfield, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Openshaw, Peter J.M. |e verfasserin |4 aut | |
| 700 | 1 | |a Semple, Malcolm G. |e verfasserin |4 aut | |
| 700 | 1 | |a Vitart, Veronique |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, James F. |e verfasserin |4 aut | |
| 700 | 1 | |a Baillie, J. Kenneth |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 15. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:15 |g month:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41586-020-03065-y |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.09.24.20200048 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 15 |c 12 | ||
| 953 | |2 045F |a 570 | ||